SCHEMBL3395256

SCHEMBL3395256

COc1c(C)ncc(CBr)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 2/20 0.42
HSP90AA1 P07900 1/20 0.41
AGXT P21549 1/20 0.35
DHFR P00374 3/20 0.33
KDM4E B2RXH2 2/20 0.33
GFER P55789 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.32
MEN1 O00255 1/20 0.30
SLC22A1 O15245 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30
NFKB1 P19838 1/20 0.30
CYP2C19 P33261 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30
LMNA P02545 1/20 0.30
MAOA P21397 1/20 0.30
PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3392208 0.81 KDM4E (0.47) HSP90AB1HSP90AA1AGXTKDM4EGFER
SCHEMBL4276650 0.81 KDM4E (0.47) HSP90AB1HSP90AA1AGXTDHFRKDM4E
SCHEMBL3393909 0.81 LMNA (0.44) HSP90AB1HSP90AA1AGXTDHFRKDM4E
SCHEMBL3797317 0.81 HSP90AB1 (0.45) HSP90AB1HSP90AA1AGXTDHFRKDM4E
SCHEMBL13015490 0.73 AGXT (0.44) HSP90AB1HSP90AA1AGXTDHFRMAOA
SCHEMBL3392251 0.72 AGXT (0.41) AGXTDHFRKDM4ELMNA
SCHEMBL14725634 0.71 NQO2 (0.36) ALDH1A1HPGDMEN1TSHRKMT2A
SCHEMBL27630752 0.71 ALDH1A1 (0.40) HSP90AB1HSP90AA1AGXTDHFRKDM4E
SCHEMBL31652002 0.69 CA2 (0.35) HSP90AB1HSP90AA1AGXTGFERALDH1A1
SCHEMBL3803205 0.69 AGXT (0.42) HSP90AB1HSP90AA1AGXTDHFRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AB1 2/4885HSP90AA1 3/4885AGXT 1906/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AB1 2/4885HSP90AA1 3/4885AGXT 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.